ライフサイエンスコーパス: pacemaker implantation

1 rillation, atrioventricular heart block, and pacemaker implantation).

2 drome, the most common reason for electronic pacemaker implantation.

3 rwent pressure-volume studies at the time of pacemaker implantation.

4 of rapid ventricular rate during AF without pacemaker implantation.

5 ith longer follow-up, and some patients need pacemaker implantation.

6 (AF) is irreversible and requires permanent pacemaker implantation.

7 ated with a lower incidence of new permanent pacemaker implantation.

8 oventricular delay for 1 week after elective pacemaker implantation.

9 fter atrioventricular (AV) node ablation and pacemaker implantation.

10 ke, valvular or congenital heart disease, or pacemaker implantation.

11 c benefits similar to those of ablation with pacemaker implantation.

12 re found highest in the patient who required pacemaker implantation.

13 dog died of cardiopulmonary arrest prior to pacemaker implantation.

14 ted CHB has an excellent prognosis following pacemaker implantation.

15 planted using techniques similar to standard pacemaker implantation.

16 in 11 patients, who then required permanent pacemaker implantation.

17 mptoms decreased in 118 patients (75%) after pacemaker implantation.

18 All the SSS variants increased the risk of pacemaker implantation.

19 system disturbances resulting in a permanent pacemaker implantation.

20 entify those at risk of heart failure before pacemaker implantation.

21 rditis, thromboembolic events, and permanent pacemaker implantation.

22 trial cardiomyopathies leading to artificial pacemaker implantation.

23 onduction abnormalities leading to permanent pacemaker implantation.

24 d repair resulted in more frequent permanent pacemaker implantation.

25 tentially life-threatening complications and pacemaker implantation.

26 nd chronic (6 months to 4 years) phases post-pacemaker implantation.

27 f residual aortic regurgitation and need for pacemaker implantation.

28 lable therapy for SSS consists of electronic pacemaker implantation.

29 major bleeding, sinus node dysfunction, and pacemaker implantation.

30 pileptic drug changes, epilepsy surgery, and pacemaker implantation.

31 developed to treat these conditions without pacemaker implantation.

32 essive atrioventricular (AV) block requiring pacemaker implantation.

33 inus node (pacemaker) disease and electronic pacemaker implantation.

34 inus syndrome (SSS), a common indication for pacemaker implantation.

35 acing sites may be considered at the time of pacemaker implantation.

36 ly 2 months and was severe enough to lead to pacemaker implantation.

37 , group A had a significantly higher rate of pacemaker implantation.

38 associated with a higher short-term rate of pacemaker implantation.

39 No patient required pacemaker implantation.

40 Twelve underwent pacemaker implantation.

41 had the highest incidence of bradycardia and pacemaker implantations.

42 Vasaloppet with incidence of bradycardia and pacemaker implantations.

43 There were no deaths, strokes, or permanent pacemaker implantations.

44 r interest is the low incidence of permanent pacemaker implantations.

45 nic shock (14.62% vs. 12.61%, p = 0.55), and pacemaker implantation (10% vs. 7.33%, p = 0.35).

46 sis (0.7% versus 0.5%), with higher rates of pacemaker implantation (11.3% versus 9.4%; P<0.001).

47 2% (95% CI: 2.1% to 4.8%); and new permanent pacemaker implantation, 13.9% (95% CI: 10.6% to 18.9%).

48 to 7.71]), conduction disturbances requiring pacemaker implantation (14.2% vs 7.3%; adjusted HR, 2.05

49 ortic valve implantation (4.0 vs. 153.4) and pacemaker implantation (147.0 vs. 831.9) compared with h

50 ere aortic regurgitation (3.5% vs. 0.5%) and pacemaker implantation (17.4% vs. 6.1%).

51 ever, BAV was associated with lower rates of pacemaker implantation (2.9% versus 8.0%; P<0.001) and b

52 similar patients who underwent ablation and pacemaker implantation ($28 302+/-2023, P<.001).

53 life, biomarkers, or functional class after pacemaker implantation; (4) after 6 months of RV pacing,

54 ery was associated with a lower incidence of pacemaker implantation (7.1%) compared with TAVR (21.0%;

55 within 12 +/- 10 months and met criteria for pacemaker implantation; 77 of 89 patients were randomly

56 the risk of a complete heart block requiring pacemaker implantation (8.1% versus 1.7%; P=0.005).

57 (adjusted OR, 1.23; 95% CI, 1.02-1.50), and pacemaker implantation (adjusted OR, 1.21; 95% CI, 1.06-

58 No patient required pacemaker implantation after a mean follow-up time of 32

59 th, rehospitalization for heart failure, and pacemaker implantation after a TAVR procedure.

60 mes of patients who have undergone permanent pacemaker implantation after aortic valve replacement re

61 ation among patients who underwent permanent pacemaker implantation after surgical aortic valve repla

62 Less than half of the patients undergoing pacemaker implantation after TAVR are pacemaker-dependen

63 isk of conduction disturbances and permanent pacemaker implantation after TAVR, with prior right bund

64 (53.5% men; median age, 81 years) underwent pacemaker implantation after TAVR.

65 e a pacemaker, whereas 23 patients underwent pacemaker implantation after the echocardiogram.

66 In patients who needed permanent pacemaker implantation after the procedure (n=35), 31.4%

67 TAVR was also associated with lower rates of pacemaker implantation after the procedure (relative ris

68 dycardia (aHR, 0.98 [95% CI, 0.75-1.30]) and pacemaker implantations (aHR, 0.98 [95% CI, 0.75-1.29])

69 d ratio [aHR], 1.19 [95% CI, 1.05-1.34]) and pacemaker implantations (aHR, 1.17 [95% CI, 1.04-1.31])

70 TAVR was associated with increased pacemaker implantation and a trend towards increased str

71 is review will discuss the role of permanent pacemaker implantation and AVNA for AF management in thi

72 ntly observed in patients after dual-chamber pacemaker implantation and can be associated with advers

73 ties for establishing central venous access, pacemaker implantation and cardiothoracic surgery.

74 s are improving over time with less need for pacemaker implantation and less significant paravalvular

75 e 2/3 were lower, whereas those of permanent pacemaker implantation and moderate/severe paravalvular

76 ients were recruited; of these, 29 underwent pacemaker implantation and were randomized to atrial rat

77 gic studies and echocardiography followed by pacemaker implantations and paced PACs (50% burden) at 2

78 ent (but had higher prevalence of stroke and pacemaker implantation) and had worse health-related qua

79 olute risk increases were 1.04% (AF), 0.53% (pacemaker implantation), and 2.05% (all-cause mortality)

80 r AF, 1.22 (95% CI, 1.14-1.30; P < .001) for pacemaker implantation, and 1.08 (95% CI, 1.02-1.13; P =

81 481 participants developed AF, 124 required pacemaker implantation, and 1739 died.

82 F, 59 (95% CI, 40-87) vs 6 (95% CI, 5-7) for pacemaker implantation, and 334 (95% CI, 260-428) vs 129

83 al is associated with increased risks of AF, pacemaker implantation, and all-cause mortality.

84 is associated with atrial fibrillation (AF), pacemaker implantation, and all-cause mortality.

85 plications, conduction disturbance requiring pacemaker implantation, and aortic regurgitation.

86 new-onset atrial fibrillation, new permanent pacemaker implantation, and aortic valve reintervention.

87 VR), mitral valve clip implantation, cardiac pacemaker implantation, and atrial fibrillation/atrial f

88 =85% for bleeding (comprehensive), permanent pacemaker implantation, and death.

89 isease (SND), atrioventricular (AV) block or pacemaker implantation, and intraventricular conduction

90 surgical or percutaneous interventions, new pacemaker implantation, and moderate or greater aortic r

91 gher risk of non-disabling stroke, permanent pacemaker implantation, and moderate or greater paravalv

92 istory of heart failure or valvular disease, pacemaker implantation, and uninterpretable electrocardi

93 ACURATE neo bioprosthesis, was new permanent pacemaker implantation at 30 days.

94 is associated with conduction abnormalities, pacemaker implantation, atrial fibrillation (AF), and ca

95 lation, 8 patients (36%) underwent permanent pacemaker implantation (atrio-ventricular blocks-5; sinu

96 the background population; the composite of pacemaker implantation, atrioventricular block, and sino

97 ive procedures such as AF catheter ablation, pacemaker implantation/atrioventricular junction ablatio

98 The incidences of stroke, bleeding, and pacemaker implantation (but not acute kidney injury) als

99 of paravalvular regurgitation and permanent pacemaker implantation, but higher transprosthetic gradi

100 h a significant higher rate of new permanent pacemaker implantation compared with the Edwards prosthe

101 nced an increased risk of new-onset HF after pacemaker implantation compared with those without AVB.

102 rs had a higher incidence of bradycardia and pacemaker implantations compared with nonskiers, a patte

103 hmia diagnoses and a significant increase in pacemaker implantations compared with usual care but no

104 atients who underwent preoperative permanent pacemaker implantation, concomitant surgical treatment f

105 r vascular complication, bleeding, permanent pacemaker implantation, death) among FFS and MA patients

106 Follow-up after dual-chamber pacemaker implantation demonstrates that nearly 30% of p

107 Patients who ultimately met criteria for pacemaker implantation did not differ from those who did

108 ard lowering the rate of reinterventions and pacemaker implantations following ASA because, in this a

109 After epicardial atrial gene transfer and pacemaker implantation for burst atrial pacing, animals

110 ence and time course for developing HF after pacemaker implantation for cAVB.

111 After NSRT, the incidence of pacemaker implantation for complete heart block was high

112 ventricular pacing in patients who underwent pacemaker implantation for isolated congenital atriovent

113 In cases of pacemaker implantation for non-life-threatening situatio

114 equency catheter ablation of the AV node and pacemaker implantation for rate control of medically ref

115 identified patients undergoing dual-chamber pacemaker implantation from 2008 to 2014.

116 plications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007.

117 are more complicated and costly than simple pacemaker implantation, future directions will be for mu

118 lectrophysiological testing, and pre-emptive pacemaker implantation have been described.

119 ed analysis, men experienced higher rates of pacemaker implantation (hazard ratio, 5.62 [95% CI, 1.57

120 .05-1.14), the composite of SND, AV-block or pacemaker implantation (HR 1.06, 95% CI 0.94-1.18), IVCB

121 .16-1.18), the composite of SND, AV-block or pacemaker implantation (HR 1.40, 95% CI 1.37-1.43), IVCB

122 5 [95% CI, 1.39-3.65; P=0.001) and permanent pacemaker implantation (HR, 1.86 [95% CI, 1.11-3.09]; P=

123 .36-3.12; P < .001), 3-fold adjusted risk of pacemaker implantation (HR, 2.89; 95% CI, 1.83-4.57; P <

124 95% CI: 0.05-0.50; P = 0.002), and permanent pacemaker implantation (HR: 0.22; 95% CI: 0.07-0.64; P =

125 urred in 11 (1.6%), stroke in 12 (1.7%), new pacemaker implantation in 127 (21.6%) of 589, moderate a

126 lar junction ablation was required in 3% and pacemaker implantation in 14%.

127 s in 2 and severe bradyarrhythmias requiring pacemaker implantation in 2.

128 ular arrhythmias in 3%, tamponade in 3%, and pacemaker implantation in 20%.

129 egree atrioventricular block in 1, permanent pacemaker implantation in 3) and excessively prolonged Q

130 usion in 17.5%, clinical stroke in 1.8%, and pacemaker implantation in 3.0%.

131 tients (p(non-inferiority)<0.0001), with new pacemaker implantation in 36 (24%) patients.

132 ated with (1) total death, sudden death, and pacemaker implantation in a model, including CTG expansi

133 , professional practice guidelines recommend pacemaker implantation in asymptomatic patients with a P

134 erm survival free of new heart failure after pacemaker implantation in isolated congenital atrioventr

135 e QRSd was obtained from 12-lead ECGs before pacemaker implantation in MOST, a 2010-patient, 6-year,

136 leads led our unit to undertake transvenous pacemaker implantation in neonates and infants from 1987

137 Data are scarce on outcomes of pacemaker implantation in nonagenarians (age>/=90 years)

138 equency catheter ablation of the AV node and pacemaker implantation in patients with atrial fibrillat

139 ars of age (n=115 683) who underwent initial pacemaker implantation in the 2004 to 2008 Healthcare Co

140 lees (73+/-10 years) undergoing dual chamber pacemaker implantation in the Protect-Pace study.

141 e training with incidence of bradycardia and pacemaker implantations, including sex differences and l

142 ident AF in patients undergoing dual chamber pacemaker implantation, independent of left atrial volum

143 mark (n=2 824 199 individuals; 5397 incident pacemaker implantations), individuals with at least 1 fi

144 cedures such as right heart catheterization, pacemaker implantation, invasive electrophysiology testi

145 PFO closure (IRR, 1.01; 99% CI, 1.00-1.02), pacemaker implantation (IRR, 1.08; 99% CI, 1.07-1.09), a

146 loping economies, there are patients in whom pacemaker implantation is delayed because they cannot af

147 However, only pacemaker implantation is predictive of long-term outcom

148 Epicardial pacemaker implantation is the favored approach in childr

149 general population, but the association with pacemaker implantations is less known.

150 had more conduction abnormalities requiring pacemaker implantation, larger improvement in effective

151 In patients who ultimately underwent pacemaker implantation LV function did not differ from t

152 Cardiac tamponade, permanent pacemaker implantation, major vascular damage, and moder

153 ndle-branch block and the need for permanent pacemaker implantation may have a significant detrimenta

154 lar complications and the need for permanent pacemaker implantation occurred more often in the TC-TAV

155 fe-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%.

156 k (TIA; OR(TAVR/SAVR), 2.03 [1.09-3.77]) and pacemaker implantation (OR(TAVR/SAVR), 1.62 [1.21-2.17])

157 e followed until first event of bradycardia, pacemaker implantation, or death, depending on end point

158 . transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant peri

159 Quality of life improved significantly after pacemaker implantation (P<0.001), but there were no diff

160 orrhage requiring transfusion, and permanent pacemaker implantation (P<0.001).

161 lar gradients (P<0.001), and a lower rate of pacemaker implantation (P=0.011).

162 11.6 to 273.9) along with need for permanent pacemaker implantation post-procedure (pooled OR: 2.6; 9

163 eft bundle branch block (LBBB) and permanent pacemaker implantation (PPI) after transcatheter aortic

164 ta exist on the clinical impact of permanent pacemaker implantation (PPI) after transcatheter aortic

165 Permanent pacemaker implantation (PPI) remains one of the main dra

166 onduction disturbances or previous permanent pacemaker implantation (PPI) who underwent TAVI with a b

167 The incidence of permanent pacemaker implantation (PPMI) due to high-grade atrioven

168 cular conduction disease requiring permanent pacemaker implantation (PPMI).

169 arch 2018, and who did not require permanent pacemaker implantation pre-discharge, were discharged wi

170 ated cardiac lesions, history of arrhythmia, pacemaker implantation, prior surgery of any type, and p

171 In contrast, AVN ablation with pacemaker implantation produces retrograde activation (s

172 In consecutive patients during HB pacemaker implantation, programmed HB pacing was deliver

173 hran-Armitage P<0.001), with fewer permanent pacemaker implantations (Q1-4: 15.3%, 20.0%, 12.1%, 11.6

174 complications (2.2% versus 6.5%), as well as pacemaker implantation rate (12.0% versus 15.2%), were s

175 No differences were observed in pacemaker implantation rate (9.8% versus 8.8%, P=0.94) a

176 ore frequently in AFib related to the higher pacemaker implantation rates (1.12 vs. 0.19 per 100 pers

177 Annual permanent pacemaker implantation rates and patient demographics we

178 ference in major aortic injury and permanent pacemaker implantation rates between groups.

179 New pacemaker implantation rates were higher for TAVR than s

180 types related to sequelae of AFib and higher pacemaker implantation rates, although the distribution

181 sfemoral; P = 0.79), bleeding complications, pacemaker implantation rates, or moderate aortic insuffi

182 d atrioventricular block requiring permanent pacemaker implantation, remain the most common complicat

183 at 30 days to 7.5% at 4 years, and permanent pacemaker implantation rose from 6.5% at 30 days to 11.7

184 time, whereas rates of cardiac tamponade and pacemaker implantation significantly increased.

185 mplications (surgical drainage of tamponade, pacemaker implantation, surgery for pulmonary vein occlu

186 Adjudicated bradyarrhythmia episodes, pacemaker implantation, syncope, and sudden cardiovascul

187 After pacemaker implantation, these seven patients reported a

188 lock underwent CMR before and 6 months after pacemaker implantation to investigate the medium-term ef

189 Consecutive patients undergoing pacemaker implantation up to 30 days after TAVR between

190 brillation was lower with TAVI, but risk for pacemaker implantation, vascular complications, and para

191 e frequency of AF during the 3 months before pacemaker implantation was analyzed.

192 Pacemaker implantation was associated with the use of a

193 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA

194 Pacemaker implantation was higher with TAVR versus SAVR

195 Pacemaker implantation was required in 2 patients (0.04%

196 Permanent pacemaker implantation was required in 3 out of 35 patie

197 Need for permanent pacemaker implantation was significantly higher with the

198 Rate of pacemaker implantation was significantly higher with the

199 Permanent pacemaker implantation was significantly lower for patie

200 r severe paravalvular leakage, and permanent pacemaker implantation was similar in the SEV and BEV gr

201 Heart block requiring permanent pacemaker implantation was the most common adverse outco

202 A higher rate of new permanent pacemaker implantations was observed in patients receivi

203 The 30-day rates of new permanent pacemaker implantation were 10.5% in the ACURATE neo gro

204 Baseline QRSd from 12-lead ECGs before pacemaker implantation were analyzed in the Mode Selecti

205 Rehospitalization for heart failure and pacemaker implantation were more frequently reported in

206 node dysfunction scheduled for dual-chamber pacemaker implantation were prospectively enrolled.

207 Patients indicated to pacemaker implantation were prospectively enrolled.

208 h heparin after implantable defibrillator or pacemaker implantation were randomized to receive intrav

209 Higher rates of prosthetic regurgitation and pacemaker implantation were seen after TAVR.

210 r severe paravalvular leakage, and permanent pacemaker implantation were similar between the BEV and

211 Patients underwent pacemaker implantation, were randomized to DDDR with the

212 developed complete heart block and underwent pacemaker implantation, whereas 1 had a preexisting pace

213 common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block i

214 Two patients have required pacemaker implantation, whereas the rest are in sinus rh

215 sion was used to investigate associations of pacemaker implantations with death in skiers and nonskie

216 The only available therapy is pacemaker implantation, with no established prevention s

217 ent, 849 patients (3.4%) underwent permanent pacemaker implantation within 30 days after surgical tre

218 rther excluded those who underwent permanent pacemaker implantation within 48 hours after the procedu

219 ted with training leads to a higher risk for pacemaker implantation without a detrimental effect on m

220 After pacemaker implantation, younger patients (</=55 years of